Onconetix subsidiary Proteomedix licenses manufacturing IP for PancreaSure test to Immunovia

Onconetix, Inc.

Proteomedix provides master cell lines and IP for three of five PancreaSure biomarkers.
Immunovia pays $700K total: two $300K payments (Sep 2025, Mar 2026) plus $100K for materials.
Immunovia to pay 3% royalty on net sales of PancreaSure from 2026 through 2032.
Deal enables Immunovia to purchase reagents directly from Proteomedix's supplier.
Onconetix remains focused on commercializing its own Proclarix prostate cancer test.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.